The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Vivian A. Fonseca

Tulane University

Medicine

New Orleans 70112

USA

[email]@tulane.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Tulane University, Medicine, New Orleans 70112, USA. 2012 - 2013
  • Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana, USA. 2003 - 2012
  • Professor of Medicine and Pharmacology, Tullis Tulane Alumni Chair in Diabetes, Section of Endocrinology, Tulane University Health Sciences Center, USA. 2008

References

  1. Saxagliptin overview: special focus on safety and adverse effects. Ali, S., Fonseca, V. Expert. Opin. Drug. Saf (2013) [Pubmed]
  2. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Fonseca, V.A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J.E. Diabetes. Care (2012) [Pubmed]
  3. Overview of metformin : special focus on metformin extended release. Ali, S., Fonseca, V. Expert. Opin. Pharmacother (2012) [Pubmed]
  4. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. Fonseca, V., Davidson, J., Home, P., Snyder, J., Jellinger, P., Dyhr Toft, A., Barnett, A. Curr. Med. Res. Opin (2010) [Pubmed]
  5. Effects of beta-blockers on glucose and lipid metabolism. Fonseca, V.A. Curr. Med. Res. Opin (2010) [Pubmed]
  6. Adding subcutaneous liraglutide to metformin reduces HbA1c more than adding oral sitagliptin in patients whose type 2 diabetes is poorly controlled with metformin alone. Fonseca, V., Desouza, C., Khan, A.N. Evid. Based. Med (2010) [Pubmed]
  7. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Fonseca, V.A., Handelsman, Y., Staels, B. Diabetes. Obes. Metab (2010) [Pubmed]
  8. Impact of a natural disaster on diabetes: exacerbation of disparities and long-term consequences. Fonseca, V.A., Smith, H., Kuhadiya, N., Leger, S.M., Yau, C.L., Reynolds, K., Shi, L., McDuffie, R.H., Thethi, T., John-Kalarickal, J. Diabetes. Care (2009) [Pubmed]
  9. Demystifying incretin therapy for type 2 diabetes. Introduction. Fonseca, V.A. Am. J. Med. (2009) [Pubmed]
  10. Demystifying incretin therapy for type 2 diabetes. Introduction. Fonseca, V.A. Eur. J. Intern. Med. (2009) [Pubmed]
  11. Defining and characterizing the progression of type 2 diabetes. Fonseca, V.A. Diabetes. Care (2009) [Pubmed]
  12. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Fonseca, V., Baron, M., Shao, Q., Dejager, S. Horm. Metab. Res. (2008) [Pubmed]
  13. Identification and treatment of prediabetes to prevent progression to type 2 diabetes. Fonseca, V.A. Clin. Cornerstone (2008) [Pubmed]
  14. Management of type 2 diabetes: oral agents, insulin, and injectables. Fonseca, V.A., Kulkarni, K.D. J. Am. Diet. Assoc (2008) [Pubmed]
  15. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Fonseca, V.A., Rosenstock, J., Wang, A.C., Truitt, K.E., Jones, M.R. Diabetes. Care (2008) [Pubmed]
  16. Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Fonseca, V., Bakris, G.L., Bell, D.S., McGill, J.B., Raskin, P., Messerli, F.H., Phillips, R.A., Katholi, R.E., Wright, J.T., Waterhouse, B., Lukas, M.A., Anderson, K.M. Diabet. Med. (2007) [Pubmed]
  17. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Fonseca, V., Schweizer, A., Albrecht, D., Baron, M.A., Chang, I., Dejager, S. Diabetologia (2007) [Pubmed]
  18. Early identification and treatment of insulin resistance: impact on subsequent prediabetes and type 2 diabetes. Fonseca, V.A. Clin. Cornerstone (2007) [Pubmed]
  19. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. Fonseca, V.A. Am. J. Med. (2007) [Pubmed]
  20. The effects of insulin on the endothelium. Fonseca, V.A. Endocrinol. Metab. Clin. North Am. (2007) [Pubmed]
  21. Identification and treatment of prediabetes to prevent progression to type 2 diabetes. Fonseca, V.A. Clin. Cornerstone (2007) [Pubmed]
  22. Commentary: the PROactive study--the glass is half full. Fonseca, V., Jawa, A., Asnani, S. J. Clin. Endocrinol. Metab. (2006) [Pubmed]
  23. Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. Fonseca, V.A., Theuma, P., Mudaliar, S., Leissinger, C.A., Clejan, S., Henry, R.R. J. Diabetes Complicat. (2006) [Pubmed]
  24. Insulin resistance, diabetes, hypertension, and renin-angiotensin system inhibition: reducing risk for cardiovascular disease. Fonseca, V.A. J. Clin. Hypertens. (Greenwich) (2006) [Pubmed]
  25. Commentary: Of HOPEs and DREAMs: the quest to prevent type 2 diabetes. Fonseca, V.A., Kahn, S.E. J. Clin. Endocrinol. Metab. (2006) [Pubmed]
  26. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments?. Fonseca, V., Jawa, A. Am. J. Cardiol. (2005) [Pubmed]
  27. The metabolic syndrome, hyperlipidemia, and insulin resistance. Fonseca, V.A. Clin. Cornerstone (2005) [Pubmed]
  28. A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Fonseca, V., Bell, D.S., Berger, S., Thomson, S., Mecca, T.E. Am. J. Med. Sci. (2004) [Pubmed]
  29. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Fonseca, V., Seftel, A., Denne, J., Fredlund, P. Diabetologia (2004) [Pubmed]
  30. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Fonseca, V. Curr. Med. Res. Opin (2003) [Pubmed]
 
WikiGenes - Universities